Glycomimetics INC 8-K Filing

Ticker: CBIO · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1253689

Glycomimetics INC 8-K Filing Summary
FieldDetail
CompanyGlycomimetics INC (CBIO)
Form Type8-K
Filed DateJan 13, 2025
Pages3
Reading Time4 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Glycomimetics INC (ticker: CBIO) to the SEC on Jan 13, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (nge on which registered Common Stock, $0.001 par value GLYC The Nasdaq Capital Mar).

How long is this filing?

Glycomimetics INC's 8-K filing is 3 pages with approximately 1,025 words. Estimated reading time is 4 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 1,025 words · 4 min read · ~3 pages · Grade level 14.3 · Accepted 2025-01-13 09:00:18

Key Financial Figures

Filing Documents

01 Regulation

Item 7.01 Regulation FD Disclosure . On January 12, 2025, GlycoMimetics, Inc. ("GlycoMimetics") and Crescent Biopharma, Inc. ("Crescent") updated the investor presentation used by them in connection with their proposed merger, which investor presentation is furnished as Exhibit 99.1 hereto and incorporated herein. No Offer or Solicitation This Current Report on Form 8-K and the exhibits filed or furnished herewith are not intended to and do not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction. NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS CURRENT REPORT ON FORM 8-K AND THE EXHIBITS FILED OR FURNISHED HEREWITH ARE TRUTHFUL OR COMPLETE. Important Additional Information About the Proposed Transaction Will be Filed with the SEC This Current Report on Form 8-K and the exhibits filed or furnished herewith are not substitutes for the Proxy Statem

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Investor Presentation, dated January 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GLYCOMIMETICS, INC. (Registrant) By: /s/ Brian M. Hahn Date: January 13, 2025 Name: Brian M. Hahn Title: Senior Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing